Last updated: February 12, 2026
Case Overview
Cummisford v. Shire US Inc is a federal civil lawsuit filed in the District of Massachusetts (docket number 1:17-cv-10156). The case involves allegations related to product liability and injury claims linked to a pharmaceutical product manufactured by Shire US Inc.
Timeline and Procedural History
- Filing Date: December 14, 2017
- Parties: Plaintiff—Eric Cummisford; Defendant—Shire US Inc.
- Jurisdiction: Federal subject matter jurisdiction based on diversity of citizenship under 28 U.S.C. § 1332.
- Initial Claims: The complaint alleges that Shire's medication caused injuries, and that the defendant failed to provide adequate warnings.
- Key Motions:
- Motion to dismiss filed by Shire US Inc. in March 2018.
- Plaintiff's opposition filed in May 2018.
- Discovery Phase: Began in late 2018; includes document production, depositions, and expert reports.
- Summary Judgment Motions: Filed in September 2020, with decisions issued in late 2020 and early 2021.
Core Legal Issues
- Product Liability: Whether Shire US Inc. manufactured, marketed, and sold a defective product.
- Failure to Warn: Whether the defendant failed to provide adequate warnings or instructions regarding risks associated with the drug.
- Causation and Damages: Whether the alleged injuries are causally linked to the medication and the extent of damages.
- Preemption and State Law Claims: Whether federal preemption precludes certain claims, and whether state-level product liability law applies.
Court Decisions and Key Points
Motion to Dismiss
- Shire US Inc. challenged the sufficiency of the complaint on multiple grounds, including lack of specificity regarding alleged injuries.
- The court denied most of the motion, emphasizing that the complaint sufficiently alleged injury causation and defendant knowledge.
Summary Judgment
- Shire US Inc. filed for summary judgment on the basis that the plaintiff could not establish causation or that the warnings were inadequate.
- The court granted summary judgment in favor of Shire on certain claims, citing the absence of admissible expert evidence linking specific injuries to the medication.
- Remaining claims related to failure to warn persisted based on evidence of post-market warnings and alleged consumer knowledge.
Expert Evidence and Causation
The case heavily relies on expert testimony:
- Plaintiff’s experts argued that the drug caused injuries based on clinical data.
- Shire’s experts challenged causation, citing alternative explanations and lack of conclusive evidence.
- The court found the expert testimony insufficient to establish a causal link for summary judgment purposes in some claims.
Settlement and Trial Status
As of the latest filings (mid-2022), the case remains active with ongoing settlement negotiations. No trial date has been set.
Legal Trends and Implications
- The case exemplifies the high evidentiary burden in product liability claims involving pharmaceuticals.
- It underscores the importance of detailed expert analysis for establishing causation.
- The court’s approach to summary judgment illustrates a preference for narrowing disputes before trial, especially around scientific causation.
Key Takeaways
- The case centers on allegations of product defect and failure to warn linked to a Shire drug.
- Plaintiff faces challenges establishing causation without robust expert evidence.
- The court has rejected some claims via summary judgment, but several remain active, indicating potential for further litigation or settlement.
- Expert testimony remains pivotal in pharmaceutical injury cases.
- Future developments depend on evidence produced during ongoing discovery and potential settlement negotiations.
FAQs
1. What drugs are involved in the case?
The complaint references a drug manufactured by Shire, believed to be related to attention deficit hyperactivity disorder (ADHD) treatment, though the exact name is not specified here.
2. What are the main defenses Shire US Inc. employs?
Shire challenges causation, asserts warnings were adequate, and argues that claims are preempted by federal regulations.
3. How does this case compare to other pharmaceutical litigation?
It reflects common issues: causation proof, expert testimony reliance, and the courts’ scrutiny of warning adequacy.
4. What is the current status?
Active with ongoing discovery efforts; no trial date scheduled; potential settlement discussions.
5. What implications does this case have for pharmaceutical companies?
Strengthens the necessity of comprehensive scientific data and transparent warning practices to defend against injury claims.
Citations
[1] Docket entries and filings, United States District Court, District of Massachusetts.
